Good
Mostly Aligned
Patient Risk:
Low
Summary
Overall, the cited COPD use aligns with the labeled indication to reduce the risk of COPD exacerbations in severe COPD with chronic bronchitis and a history of exacerbations. However, some claims about generic/brand naming and manufacturer listing are not supported by the provided prescribing-information excerpts.
Category Scores
Accurate Statements
Roflumilast is used in the management of COPD (chronic obstructive pulmonary disease).
Supported indirectly: DALIRESP (roflumilast) is indicated to reduce the risk of COPD exacerbations in severe COPD associated with chronic bronchitis and a history of exacerbations (Section 1 INDICATIONS AND USAGE). The claim is consistent with the COPD-focused labeled indication and purpose (risk of exacerbations).
Unsupported Statements
Daliresp’s generic name is roflumilast.
The provided label excerpts do not state that Daliresp is a brand name whose generic is roflumilast.
Daliresp is a brand name for the medication roflumilast.
The provided label excerpts do not define Daliresp as a brand name or equate it to roflumilast.
The medicine may be listed under the INN/generic name roflumilast across different manufacturers because Daliresp is the brand.
No information in the provided prescribing-information excerpts addresses INN/generic listing across manufacturers or brand-to-manufacturer listing conventions.
Contradictions
Important Omissions
The labeled indication is specifically to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations (not general COPD management).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-aligned clinical use statement concerns COPD exacerbation risk reduction, which is consistent with the label’s COPD indication. Unsupported naming/listing statements pose no direct clinical safety risk.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Clinical indication wording is overly broad ("management of COPD") and naming/listing claims are not supported by the provided label excerpts.
Suggested Improvement
Rephrase the COPD claim to match the label intent and population: reducing the risk of COPD exacerbations in severe COPD with chronic bronchitis and a history of exacerbations. Remove or omit brand/generic/INN-by-manufacturer listing statements unless supported by the provided labeling text.